He and the board are leading an evolution in the culture, but still very much doing things in ‘the Novo Nordisk way’ – which boils down to pursuing innovation with a Nordic attention to ...

New competitors could make their way through trials and into the market over the next five years, but Novo Nordisk's lucrative share of the GLP-1 agonist market seems intact for now, to say the least.

a small-molecule drug designed to boost calorie expenditure in the body as a way to combat obesity. As part of the deal, Novo Nordisk has entered into a three-year collaboration with Embark ...

Novo Nordisk stock dropped Monday after the drugmaker licensed a Chinese competitor's diabetes and weight-loss drug for up to $2 billion. Novo will pay The United Laboratories International $200 ...

Novo Nordisk may be reorganizing its early-stage ... “This journey started way before any of us actually knew what the outcome of CagriSema [was], and it actually, regardless of this outcome ...

(Pfizer stock was down 1.2% in the same time frame, by the way). The implications for Eli Lilly and Novo Nordisk seem pretty clear: The immediate removal of a rival for the massive revenues they ...

Less than five years on from when Novo Nordisk's semaglutide drug received ... It works in a similar way to just semaglutide, but may offer better glycemic control and higher weight-loss outcomes.

In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against other stocks that market experts are talking about these days. Piper Sandler’s Chief Market ...